Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients
23 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 23, 2014) - Nuvilex (OTCQB: NVLX) is calling it a "two pronged attack" on pancreatic cancer, but investors may be calling it an "end-around" or another avenue of...
Nuvilex Positioned for Lucrative Deal With Cell-in-a-Box Technology's Diverse Treatments Amid Biotech Frenzy
20 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is up to much more than most are currently aware of, and it only takes a bit of digging to realize it. The company is clearly...
Nuvilex: A Biotech Methodically Pursuing Cannabis Treatments for Cancer
13 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 13, 2014) - Nuvilex, Inc. (OTCQB: NVLX) announced last week that it signed an agreement with the University of Northern Colorado to perform initial studies in the...
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
07 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 7, 2014) - Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA...
Nuvilex, Inc.'s Cell-in-a-Box Treatment Called Magic Bullets of 21st Century by World Renowned Oncologist
05 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 5, 2014) - Nuvilex, Inc. (OTCQB: NVLX) continued to awe investors last week with yet another marquee name that has agreed to work with its pancreatic cancer...
Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment Without Competition
22 avr. 2014 08h45 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 22, 2014) - When Nuvilex, Inc. (OTCQB: NVLX) named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in...
Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial
17 avr. 2014 08h45 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 17, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has once again delivered a major announcement as it advances its pancreatic cancer treatment toward late phase clinical...
Nuvilex Investors Should Read Between the Lines as Company Attracts World Renowned Oncologist
03 avr. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 3, 2014) - That loud noise you hear coming from Nuvilex, Inc. (OTCQB: NVLX) this week is the collective excitement of many investors after the company stated it...
Nuvilex Funding Has Investors Preparing for Milestone Announcements in Late-Phase Clinical Trials
03 mars 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Mar 3, 2014) - Nuvilex (OTCQB: NVLX) investors who have patiently waited for the R&D biotech to reach a point where late-phase clinical trials were a reality, are...
Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly
24 févr. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 24, 2014) - Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be...